These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 15868915

  • 1. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
    Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T.
    Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
    [Abstract] [Full Text] [Related]

  • 2. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M.
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [Abstract] [Full Text] [Related]

  • 3. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K, Shimazu M, Suzuki M, Itoi T, Aoki T, Tsuchida A.
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [Abstract] [Full Text] [Related]

  • 4. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M.
    Clin Cancer Res; 2007 Mar 15; 13(6):1875-82. PubMed ID: 17363544
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
    Okita R, Yamaguchi Y, Emi A, Matsuura K, Toge T.
    Oncol Rep; 2007 Jun 15; 17(6):1429-35. PubMed ID: 17487401
    [Abstract] [Full Text] [Related]

  • 6. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
    zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H.
    Cancer Res; 2002 Apr 15; 62(8):2244-7. PubMed ID: 11956077
    [Abstract] [Full Text] [Related]

  • 7. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, Moriyasu F, Nieda M, Nicol AJ.
    Int J Cancer; 2008 Jun 01; 122(11):2526-34. PubMed ID: 18307255
    [Abstract] [Full Text] [Related]

  • 8. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Ménard S, Costa A, Fagnoni FF.
    Cancer Res; 2007 Dec 15; 67(24):11991-9. PubMed ID: 18089830
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W, Shau H, Hadley CG, Morgan AC, Reisfeld RA, Cheresh DA, Mitchell MS.
    Cancer Res; 1990 Oct 01; 50(19):6311-5. PubMed ID: 2400994
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y.
    Anticancer Res; 1998 Oct 01; 18(1A):17-24. PubMed ID: 9568050
    [Abstract] [Full Text] [Related]

  • 16. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G.
    Clin Cancer Res; 2004 Jul 01; 10(13):4489-97. PubMed ID: 15240541
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
    Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.
    Cancer Res; 2009 Oct 15; 69(20):8058-66. PubMed ID: 19826050
    [Abstract] [Full Text] [Related]

  • 19. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].
    Chen QK, Yuan SZ.
    Zhonghua Zhong Liu Za Zhi; 1994 Sep 15; 16(5):353-5. PubMed ID: 7895586
    [Abstract] [Full Text] [Related]

  • 20. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
    Ting CC, Hargrove ME, Yun YS.
    J Immunol; 1988 Aug 01; 141(3):741-8. PubMed ID: 3260909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.